How to Qualify for Ozempic: The Screening Checklist Used in Practice

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited · Author: FormBlends Editorial

Key Takeaways

• Ozempic itself has no BMI requirement; the on-label path is type 2 diabetes (HbA1c at or above 6.5%)
• Weight-loss qualification routes through Wegovy: BMI 30+, or BMI 27+ with weight-related comorbidity
• Insurance generally requires documentation of diagnosis plus lifestyle or prior-medication trials
• Cash-pay and compounded paths exist for patients who do not qualify under insurance but meet clinical criteria
• Several disqualifications are categorical: MTC history, MEN-2, pregnancy, severe hypersensitivity

Direct answer

To qualify for Ozempic on label, you need a type 2 diabetes diagnosis as an adult 18 or older. For weight-loss qualification, the relevant on-label option is Wegovy (semaglutide for obesity), requiring BMI 30+ or BMI 27+ with at least one comorbidity. Both pathways exclude patients with personal or family history of medullary thyroid carcinoma, MEN-2, pregnancy, severe hypersensitivity to semaglutide, or active pancreatitis. Insurance coverage adds layered documentation requirements; cash-pay and compounded paths exist for patients who meet clinical but not coverage criteria.

Table of contents

1. Two different qualification paths
2. The type 2 diabetes path (Ozempic on label)
3. The obesity path (Wegovy on label)
4. The BMI threshold breakdown
5. Qualifying comorbidities for the 27+ pathway
6. Insurance documentation requirements
7. What disqualifies a patient
8. Cash-pay and compounded paths when insurance declines
9. Contrary view: are BMI cutoffs the right gate
10. Decision framework
11. FAQ
12. Sources

Two different qualification paths

Patients searching "how to qualify for Ozempic" generally mean one of two things: how to qualify for semaglutide for diabetes management, or how to qualify for semaglutide for weight loss. The qualification criteria differ.

• Diabetes path: Ozempic (Novo Nordisk brand), FDA-approved for type 2 diabetes. Dose ceiling 2 mg weekly.
• Obesity path: Wegovy (same molecule, different label), FDA-approved for obesity. Dose ceiling 2.4 mg weekly.

The active ingredient is identical. The qualification criteria, insurance pathway, and labeled use differ.

The type 2 diabetes path (Ozempic on label)

Standard qualification criteria for on-label Ozempic prescribing:

• Adult age 18 or older
• Documented type 2 diabetes (HbA1c 6.5% or higher on at least one occasion, or fasting glucose 126 mg/dL or higher on two occasions, or 2-hour OGTT 200 mg/dL or higher, or random glucose 200 mg/dL with symptoms)
• Active diabetes diagnosis in clinical records (ICD-10 E11.x or similar)
• No contraindications (boxed warning or absolute exclusions)

Many insurance plans require additional steps before approving Ozempic specifically (rather than other GLP-1 agonists or other diabetes medications):

• Trial of metformin first, unless contraindicated
• HbA1c above a threshold (often 7.5%) demonstrating inadequate control on prior therapy
• BMI 27+ in some plans (a coverage rule, not an FDA rule)
• Endocrinology referral in some plans

The obesity path (Wegovy on label)

Wegovy qualification criteria:

• Adult age 18+ OR adolescent age 12-17 with body weight greater than 60 kg
• Adult BMI 30 or higher (obesity), OR
• Adult BMI 27 or higher (overweight) with at least one weight-related comorbidity, OR
• Adolescent BMI at or above the 95th percentile for age and sex
• Used as adjunct to reduced-calorie diet and increased physical activity
• No contraindications

The 2023 SELECT trial expansion added an additional indication: reduction of major adverse cardiovascular events in adults with established cardiovascular disease and BMI 27+, regardless of diabetes status. This is relevant for some insurance coverage decisions, particularly Medicare.

The BMI threshold breakdown

BMI Range	Category	Wegovy Eligibility
Under 25	Normal weight	Not eligible
25.0-26.9	Overweight	Not eligible (does not meet 27 threshold)
27.0-29.9	Overweight	Eligible only if at least one comorbidity is present
30.0-34.9	Class 1 obesity	Eligible
35.0-39.9	Class 2 obesity	Eligible
40.0+	Class 3 obesity (severe)	Eligible; bariatric surgery also considered

BMI is calculated as weight in kilograms divided by height in meters squared. Online calculators are accurate. The body composition limitation of BMI (it does not distinguish muscle from fat) matters most at the margins: a muscular patient with BMI 27 may not have the metabolic risk that the threshold is designed to capture.

Qualifying comorbidities for the 27+ pathway

The FDA-recognized comorbidities that qualify a patient with BMI 27-29.9 for Wegovy:

• Hypertension (blood pressure at or above 130/80 on confirmed measurement, or on antihypertensive medication)
• Dyslipidemia (LDL cholesterol elevation, low HDL, high triglycerides, or on lipid-lowering medication)
• Type 2 diabetes (which would also qualify for the diabetes path)
• Obstructive sleep apnea (documented by sleep study; the most recent Zepbound expansion also covers OSA as a primary indication for tirzepatide)
• Cardiovascular disease (history of myocardial infarction, stroke, heart failure, or coronary artery disease)

Other conditions commonly considered but not always accepted by insurance: nonalcoholic fatty liver disease, polycystic ovary syndrome, prediabetes (HbA1c 5.7-6.4%), gastroesophageal reflux, osteoarthritis weight-related.

Insurance documentation requirements

Insurance prior authorization for Wegovy typically requires submitting:

1. Current BMI calculation with documented height and weight
2. Comorbidity documentation if BMI 27-29.9 (lab results, imaging, specialist notes)
3. Documented prior lifestyle intervention attempt (often 6 months minimum)
4. Diet and exercise plan documentation
5. Sometimes: prior pharmacotherapy trial (phentermine, topiramate, naltrexone-bupropion, or orlistat)
6. Confirmation of no contraindications

Some plans add step-therapy requirements: patients must try an older or less expensive medication first and document inadequate response before Wegovy is approved. The specific step depends on the plan formulary.

Medicare typically does not cover obesity-focused Wegovy. The cardiovascular indication (SELECT-based) is covered when patients meet established cardiovascular disease criteria with BMI 27+.

What disqualifies a patient

Absolute disqualifications (no GLP-1 therapy regardless of pathway):

• Personal history of medullary thyroid carcinoma
• Family history of MTC in a first-degree relative
• Multiple Endocrine Neoplasia syndrome type 2
• Active or planned pregnancy within the next 2 months
• Severe hypersensitivity to semaglutide
• Active pancreatitis

Relative disqualifications (case-by-case):

• Prior pancreatitis episode
• Severe gastroparesis
• Active eating disorder
• Active gallbladder disease
• Moderate to severe diabetic retinopathy without ophthalmology clearance
• Active suicidal ideation
• Severe hepatic impairment
• End-stage renal disease

Cash-pay and compounded paths when insurance declines

Patients who meet clinical criteria but face insurance denial have options:

Brand cash-pay. Ozempic and Wegovy retail at roughly $1,000-$1,200 per month without insurance. Manufacturer savings cards from Novo Nordisk require commercial insurance to activate and are not available to cash-pay patients.

Lilly Direct (for tirzepatide, not semaglutide). Eli Lilly's direct-to-consumer cash-pay program for Zepbound (LillyDirect Self Pay Journey Program) priced at $349 per month for 2.5 mg single-dose vials in 2024, scaling up for higher doses. This is a Zepbound-only program; there is no equivalent manufacturer cash-pay for Ozempic or Wegovy.

Compounded semaglutide via 503A pharmacy. Typically $200-$500 per month depending on dose and pharmacy. Requires a prescription from a licensed clinician who documents clinical necessity. Compounded products are not FDA-approved and are not interchangeable with brand Ozempic or Wegovy.

Manufacturer patient assistance. Novo Nordisk's Novo Cares program provides medication at reduced or no cost to qualifying low-income patients without insurance. Income thresholds vary by year; the application requires proof of income and uninsured status.

Contrary view: are BMI cutoffs the right gate

The BMI 30 / BMI 27 + comorbidity criteria date to early obesity pharmacotherapy guidelines from the 1990s. Two critiques:

BMI captures size, not metabolic health. Patients with metabolically unhealthy normal weight (insulin resistance, dyslipidemia, fatty liver) at BMI 23-26 may benefit from GLP-1 therapy more than some patients meeting the 30 cutoff. The 2024 American Association of Clinical Endocrinologists position statement called for moving beyond BMI alone toward Adiposity-Based Chronic Disease (ABCD) staging.

Ethnic and sex differences in body composition. South Asian and East Asian patients develop metabolic complications at lower BMI than the BMI 30 cutoff suggests. Some clinicians use BMI 27.5 or 25 as Asian-adjusted thresholds.

The counter: BMI is reproducible, cheap, and gives a workable population gate. Replacing it with multi-component metabolic staging requires lab access, training, and standardization that the current healthcare system has not delivered. The 30/27+ cutoff is imperfect but operational.

The pragmatic position: meet the current criteria where you can, push for individualized assessment where you can, and use case-by-case clinician judgment within the legal scope of practice.

Decision framework

HbA1c 6.5% or higher: Type 2 diabetes path. On-label Ozempic with standard insurance coverage. Discuss with primary care or endocrinology.

BMI 30+ without diabetes: Obesity path. On-label Wegovy. Document lifestyle attempt for prior authorization.

BMI 27-29.9 with hypertension, dyslipidemia, OSA, or CVD: Obesity path. On-label Wegovy with comorbidity documentation.

BMI 27-29.9 without listed comorbidity: Typically not eligible for on-label Wegovy. Discuss with clinician; some prescribe off-label or via compounded path.

BMI under 27: Not eligible for on-label GLP-1 therapy in most settings. Lifestyle, behavioral, and metabolic workup are the appropriate focus.

Boxed warning positive: Not eligible. Discuss alternative therapies with your clinician.

FAQ

How do I qualify for Ozempic? Adult, type 2 diabetes diagnosis (HbA1c 6.5%+), no boxed warning contraindications. For weight loss, Wegovy criteria apply: BMI 30+ or BMI 27+ with comorbidity.

What BMI do I need for Ozempic? Ozempic itself has no BMI rule; it is approved for diabetes. Wegovy requires BMI 30+ or 27+ with comorbidity.

What A1c do I need for Ozempic? 6.5% or higher meets the diabetes diagnostic criteria. Some insurance plans require 7.5%+ for prior authorization.

Can I get Ozempic for weight loss only? Sometimes off-label, rarely covered by insurance. Most weight-loss patients are routed to Wegovy or compounded semaglutide.

What documentation does insurance require for Ozempic? HbA1c, diabetes diagnosis code, sometimes metformin trial documentation. Wegovy adds BMI documentation, comorbidity documentation, and lifestyle intervention records.

How do I document prior lifestyle attempts for Wegovy prior authorization? Clinic notes with specific date ranges, weights, programs tried, dietitian visits, or prior medication trials. Self-report alone is rarely sufficient.

Can I qualify without insurance? Yes, through cash-pay or compounded paths. Compounded semaglutide typically runs $200-$500 per month vs. $1,000-$1,200 cash-pay for brand.

What disqualifies me from Ozempic? MTC history, MEN-2, pregnancy, severe hypersensitivity, active pancreatitis. Relative exclusions include prior pancreatitis, severe gastroparesis, active eating disorder.

Sources

1. FDA. Ozempic Prescribing Information. Current revision 2025.
2. FDA. Wegovy Prescribing Information, including SELECT cardiovascular indication. Current revision 2025.
3. American Diabetes Association. Standards of Medical Care in Diabetes, 2025.
4. Endocrine Society. Pharmacological Management of Obesity: Clinical Practice Guideline. 2023 update.
5. American Association of Clinical Endocrinologists. Adiposity-Based Chronic Disease (ABCD) Framework: Position Statement. 2024.
6. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes (SELECT). NEJM. 2023.
7. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM. 2021.
8. Centers for Medicare and Medicaid Services. Anti-Obesity Drug Coverage Determination Update. 2025.
9. Novo Nordisk. Novo Cares Patient Assistance Program: Eligibility and Application. 2025.
10. National Association of Insurance Commissioners. State-Level Coverage of Anti-Obesity Medications. Survey, 2024.
11. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004.
12. Garvey WT et al. American Association of Clinical Endocrinologists Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016 with updates.

Footer disclaimers

Platform Disclaimer. FormBlends connects patients with independent licensed clinicians and U.S.-based pharmacies. Qualification for any medication is a clinical decision made by an independent provider after evaluation. Insurance prior authorization rules vary by plan.

Compounded Medication Notice. Compounded semaglutide is prepared by a state-licensed 503A pharmacy in response to an individual prescription. It is not FDA-approved and is not interchangeable with brand Ozempic or Wegovy.

Results Disclaimer. Trial outcomes cited (STEP 1, SELECT) reflect average study results in study populations. Individual response varies based on adherence, baseline weight, diet, exercise, and metabolic factors.

Trademark Notice. Ozempic and Wegovy are trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are trademarks of Eli Lilly and Company. Novo Cares is a Novo Nordisk patient assistance program. FormBlends is not affiliated with Novo Nordisk or Eli Lilly.